[1] MASATO FURUHASHI. Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2[J]. Nature, 2007, 447 7147: 959-965. DOI:
10.1038/nature05844[2] RICHARD SULSKY . Potent and selective biphenyl azole inhibitors of adipocyte fatty acid binding protein (aFABP)[J]. Bioorganic & Medicinal Chemistry Letters, 2007, 17 12: Pages 3511-3515. DOI:
10.1016/j.bmcl.2006.12.044[3] WANHUA LIN. BMS309403 stimulates glucose uptake in myotubes through activation of AMP-activated protein kinase.[J]. PLoS ONE, 2012: e44570. DOI:
10.1371/journal.pone.0044570[4] ALBA BOSQUET. FABP4 inhibitor BMS309403 decreases saturated-fatty-acid-induced endoplasmic reticulum stress-associated inflammation in skeletal muscle by reducing p38 MAPK activation[J]. Biochimica et biophysica acta. Molecular and cell biology of lipids, 2018, 1863 6: Pages 604-613. DOI:
10.1016/j.bbalip.2018.03.004[5] YUANQI GONG . FABP4 inhibitors suppress inflammation and oxidative stress in murine and cell models of acute lung injury[J]. Biochemical and biophysical research communications, 2018, 496 4: Pages 1115-1121. DOI:
10.1016/j.bbrc.2018.01.150